D. Kirn

发表

Treatment of p53-Deficient Cancers by Adenovirus E1B-Region Mutants

D. Kirn, 2000 .

Oncolytic biotherapy: a novel therapeutic plafform.

D. Kirn, N. Lemoine, L. Hawkins, 2002, The Lancet. Oncology.

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.

R. Warren, D. Kirn, 2002, Surgical oncology clinics of North America.

CHAPTER 29 – Virotherapy with Replication-Selective Oncolytic Adenoviruses: A Novel Therapeutic Platform for Cancer

D. Kirn, 2002 .

Replication-Selective Oncolytic Adenovirus E1-Region Mutants: Virotherapy for Cancer

D. Kirn, 2002 .

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

D. Kirn, 2000, Oncogene.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

R. Patt, D. Kirn, M. K. Kim, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

D. Kirn, C. Breitbach, J. Bell, 2015, Current opinion in virology.

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

D. Kirn, C. Breitbach, A. Moon, 2015, Methods in molecular biology.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

R. Patt, D. Kirn, S. Thorne, 2013, Cancer research.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

M. Bloomston, R. Patt, R. Lencioni, 2013, Nature Medicine.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Jiwon Kim, D. Kirn, S. Thorne, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

H. Atkins, D. Kirn, C. Breitbach, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus

D. Kirn, S. Thorne, J. Bell, 2007, PLoS medicine.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

D. Sze, D. Kirn, S. Han, 2008, The Lancet. Oncology.

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

D. Kirn, J. Bell, T. Hwang, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

E. Galanis, D. Kirn, Ta-Chiang Liu, 2007, Nature Clinical Practice Oncology.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

D. Kirn, S. Thorne, David H. Kirn, 2009, Nature Reviews Cancer.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Aaron Fenster, James Burke, Andrew R. Haas, 2011, Nature.

Targeting tumor vasculature with an oncolytic virus.

H. Atkins, A. Fenster, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma

D. Kirn, D. Soutar, Robert Brown, 2004, Clinical Cancer Research.

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma

D. Kirn, D. Soutar, Robert Brown, 2004 .

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma.

S. Rosenfeld, E. Chiocca, K. Judy, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

M. Gore, L. Shulman, D. Kirn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.

D. Alberts, D. Kirn, R. Alvarez, 2008, Gynecologic oncology.

Virotherapy for cancer: Current status, hurdles, and future directions

D. Kirn, 2002, Cancer Gene Therapy.

ONYX-015: Clinical data are encouraging

F. McCormick, T. Hermiston, D. Kirn, 1998, Nature Medicine.

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

C. Contag, C. Kuo, D. Kirn, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status

Cesario Z. Cerna, D. V. Von Hoff, T. Petit, 2002, Anti-cancer drugs.

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

P. Opolon, B. Geoerger, G. Vassal, 2003, British Journal of Cancer.

A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck.

D. Kirn, 2000, Methods in molecular medicine.

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

M. Lemmon, D. Kirn, C. Heise, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

D. Kirn, D. Bartlett, S. Thorne, 2005, Current gene therapy.

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

H. Atkins, D. Kirn, C. Breitbach, 2010, Cytokine & growth factor reviews.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis

H. Atkins, J. Diallo, B. Vanderhyden, 2008, Proceedings of the National Academy of Sciences.

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

E. Small, G. Wilding, M. Carducci, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

A. Venook, R. Warren, D. Kirn, 2001, Gene Therapy.

Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.

D. Kirn, T. Hermiston, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeted genetic and viral therapy for advanced head and neck cancers.

D. Kirn, Ta-Chiang Liu, Pin-I Huang, 2009, Drug discovery today.

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

D. Kirn, S. Thorne, B. Huang, 2011, Gene Therapy.

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

D. Sze, E. Galanis, J. Abbruzzese, 2001, Gene Therapy.

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver

D. Sze, D. Kirn, S. Thorne, 2006, Cancer Gene Therapy.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Joon-Oh Park, R. Patt, S. Park, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma

D. Kirn, J. Chan, Beicheng Sun, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing

D. McDonald, D. Kirn, Mitsuko Inoue, 2021, Molecular Cancer Therapeutics.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

D. Kirn, H. Zeh, D. Bartlett, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

C. Rooney, D. Kirn, C. Breitbach, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.

D. Kirn, A. Makrigiannis, L. Tai, 2013, Cancer research.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

D. Kirn, S. Thorne, C. Breitbach, 2012, Current pharmaceutical biotechnology.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

J. Diallo, A. Ribas, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

D. Kirn, J. Bell, T. Hwang, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

C. Contag, D. Kirn, S. Thorne, 2008, Cancer Research.

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

T. Hermiston, D. Kirn, S. Thorne, 2005, Seminars in oncology.

The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

R. Vile, D. Kirn, D. Ando, 2002, Cancer Gene Therapy.

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model

D. Kirn, T. Hwang, M. Roh, 2009, Cancer Gene Therapy.

Synergistic interaction between oncolytic viruses augments tumor killing.

H. Atkins, J. Diallo, D. Kirn, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers.

H. Atkins, E. Brown, J. Diallo, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging.

D. Sugarbaker, T. Lynch, G. Strauss, 1993, The Journal of thoracic and cardiovascular surgery.

Mediastinal Large Cell Lymphoma: Prognostic Significance ofCT Findings at Presentation and after Treatment

L. Shulman, D. Kirn, G. Canellos, 1998, Oncology.

Phase I I T rial o f I ntratumoral A dministration o f O NYX- 015, a R eplication-Sele ctive A denovirus, i n P atients W ith Refractory H ead a nd N eck C ancer

F. Khuri, J. Nemunaitis, E. Vokes, 2001 .

Development of targeted oncolytic virotherapeutics through translational research

D. Kirn, J. Bell, T. Hwang, 2008 .

Monthly Update: Oncologic, Endocrine & Metabolic: Replicating oncolytic viruses: An overview

D. Kirn, 1996 .

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

D. Kirn, Ta-Chiang Liu, 2007, Cancer research.

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects

D. Kirn, C. Heise, Angelica Williams, 1999, Cancer Gene Therapy.

Oncolytic Viruses: Methods and Protocols

D. Kirn, S. Thorne, Ta-Chiang Liu, 1972, Nature.

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma.

S. Rosenfeld, E. Chiocca, K. Judy, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Approaches to the Gene Therapy of Cancer Using Replication-Competent Oncolytic Adenoviruses

A. Balmain, D. Kirn, C. Heise, 1998 .

A tale of two trials: selectively replicating herpesviruses for brain tumors

D. Kirn, 2000, Gene Therapy.

Oncolytic virotherapy as a novel treatment platform for cancer.

D. Kirn, 2003, Ernst Schering Research Foundation workshop.

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

D. Kirn, F. McCormick, D. V. Hoff, 1997, Nature Medicine.

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus

Yufei Wang, D. Kirn, N. Lemoine, 2005, Gene Therapy.

Oncolytic Activity of the E 1 B-55 kDa-deleted Adenovirus ONYX-015 Is Independent of Cellular p 53 Status in Human Malignant Glioma Xenografts 1

P. Opolon, B. Geoerger, G. Vassal, 2002 .

Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status

I. Ganly, R. Brown, D. Kirn, 2000, Gene Therapy.

Advances in Brief In Vivo Antitumor Activity of ONYX-015 Is Influenced by p 53 Status and Is Augmented by Radiotherapy 1

J. H. Kim, D. Kirn, S. Freytag, 2000 .

Targeting the untargetable: oncolytic virotherapy for the cancer stem cell.

D. Kirn, Ta-Chiang Liu, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

D. Kirn, J. H. Kim, S. Freytag, 2000, Cancer research.

Problems, Side Effects, and Disappointments in Clinical Cancer Gene Therapy

D. Kirn, Ta-Chiang Liu, 2007 .

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

J. Hecht, R. Soetikno, J. Abbruzzese, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

L. Wein, D. Sze, E. Galanis, 2002, Cancer research.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

J. Nemunaitis, G. Netto, D. Kirn, 2001, Gene Therapy.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

F. Khuri, J. Nemunaitis, I. Ganly, 2000, Cancer research.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

I. Tannock, F. Khuri, W. Hong, 2000, Nature Medicine.

An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

A. Fattaey, D. Kirn, J. Bischoff, 1996, Science.

The emerging fields of suicide gene therapy and virotherapy.

C. Springer, D. Kirn, I. Niculescu-Duvaz, 2002, Trends in molecular medicine.

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.

D. Kirn, N. Lemoine, Yaohe Wang, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

R. Hill, D. Kirn, N. Lemoine, 2003, Nature Biotechnology.

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration.

D. Kirn, S. Thorne, T. Wickham, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

P. Opolon, B. Geoerger, G. Vassal, 2002, Cancer research.

Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials

D. Kirn, 2001, Expert opinion on biological therapy.

An essential role for Rac in Ras transformation

F. McCormick, M. Symons, D. Kirn, 1995, Nature.

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

D. Kirn, N. Lemoine, S. Thorne, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Viruses with deletions in antiapoptotic genes as potential oncolytic agents

D. Kirn, Ta-Chiang Liu, 2005, Oncogene.

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

R. Martuza, D. Kirn, James Zwiebel, 2001, Nature Medicine.

Pulmonary aspergillosis masquerading as progressive post‐transplant lymphoma

A. Venook, D. Kirn, I. Penn, 1996 .

Pulmonary aspergillosis masquerading as progressive post-transplant lymphoma

A. Venook, D. Kirn, I. Penn, 1996, Transplant international : official journal of the European Society for Organ Transplantation.

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

F. Khuri, J. Nemunaitis, E. Vokes, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

J. Burke, R. Patt, R. Lencioni, 2019, Oncoimmunology.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

H. Atkins, J. Diallo, D. Kirn, 2015, Cancer cell.

Gene therapy progress and prospects cancer: oncolytic viruses

D. Kirn, T-C Liu, D Kirn, 2008, Gene Therapy.

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

L. Johnson, T. Hermiston, D. Kirn, 2000, Nature Medicine.

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

M. Gulley, D. V. Von Hoff, I. Ganly, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interleukin-1β and tumour necrosis factor-α promote the transformation of human immortalised mesothelial cells by erionite

C. E. Houghton, D. Kirn, N. Lemoine, 2004 .

Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

C. E. Houghton, D. Kirn, N. Lemoine, 2004, International journal of oncology.

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

D. Kirn, 2001, Gene Therapy.

Oncolytic adenoviruses for cancer gene therapy.

D. Kirn, S. Thorne, Ta-Chiang Liu, 2008, Methods in molecular biology.

Vaccinia virus and oncolytic virotherapy of cancer.

D. Kirn, S. Thorne, T. Hwang, 2005, Current opinion in molecular therapeutics.

Intravascular adenoviral agents in cancer patients: Lessons from clinical trials

R. Warren, D. Kirn, T. Reid, 2002, Cancer Gene Therapy.

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

D. Kirn, Anne Moon Crompton, A. Crompton, 2007, Current cancer drug targets.

Armed interference: oncolytic viruses engineered to carry antitumor shRNAs.

D. Kirn, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

R. Hill, D. Kirn, N. Lemoine, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

D. McDonald, D. Kirn, C. Breitbach, 2018, Cancer research.

Phase II Tria l o f Intratumoral Adminis trat ion of ONYX-015 , a Repl icat ion-Select i ve Adenovirus , in Pat ients With Refractory Head and Neck Cancer

F. Khuri, J. Nemunaitis, E. Vokes, 2000 .

Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients.

G. Pinkus, M. Shipp, D. Kirn, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma.

D. Kirn, C. Tsao, I. Chen, 2009, Lung cancer.

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

D. Kirn, M. K. Kim, C. Breitbach, 2013, Science Translational Medicine.

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

D. Kirn, S. Thorne, 2004, Expert opinion on biological therapy.

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

Lawrence M Wein, L. Wein, D. Kirn, 2003, Cancer research.

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

D. Kirn, C. Breitbach, J. Bell, 2010, Cytokine & growth factor reviews.

Replicating viruses as selective cancer therapeutics.

D. Kirn, F. McCormick, D H Kirn, 1996, Molecular medicine today.

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response

L. Wein, D. Kirn, Joseph T. Wu, 2004, Bulletin of mathematical biology.

Modeling and analysis of a virus that replicates selectively in tumor cells

L. Wein, H. Byrne, D. Kirn, 2001, Bulletin of mathematical biology.

Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation.

L. Shulman, D. Kirn, G. Canellos, 1996, AJR. American journal of roentgenology.

Complement-Dependent Cancer Cell Lysis in Humans Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated

D. Kirn, M. K. Kim, C. Breitbach, 2013 .

Induction of an oncogenic fusion protein by a viral gene—a new chapter in an old story

T. Hermiston, D. Kirn, 1999, Nature Medicine.

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

H. Atkins, J. Diallo, D. Kirn, 2010, PloS one.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

D. Kirn, D. Bartlett, S. Thorne, 2007, The Journal of clinical investigation.

Section Review: Oncologic, Endocrine & Metabolic: New treatment approaches for metastatic breast cancer

D. Kirn, 1995 .

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

J. Diallo, B. Vanderhyden, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic virotherapy for advanced liver tumours

D. Sze, D. Kirn, D. Bartlett, 2008, Journal of cellular and molecular medicine.

Replication-selective oncolytic adenoviruses.

D. Kirn, S. Thorne, G. Halldén, 2004, Methods in molecular medicine.

Replication-selective microbiological agents: fighting cancer with targeted germ warfare.

D. Kirn, 2000, The Journal of clinical investigation.

Replication-selective adenoviruses as oncolytic agents.

D. Kirn, C. Heise, 2000, The Journal of clinical investigation.

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.

D. Kirn, C. Heise, A. Williams, 1999, Cancer research.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

John D Lambris, C. Findlay, H. Atkins, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

D. Kirn, C. Breitbach, J. Bell, 2015, Oncolytic virotherapy.

MicroRNAs fine-tune oncolytic viruses

D. Kirn, J. Bell, 2008, Nature Biotechnology.

The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept.

D. Kirn, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models

R. Hill, D. Kirn, N. Lemoine, 2008, Cancer Gene Therapy.

Molecular and Cellular Pathobiology Ampli fi cation of FRS 2 andActivation of FGFR / FRS 2 Signaling Pathway in High-Grade Liposarcoma

So, Hanlin Gao, Jinhui Wang, 2013 .

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

D. Sze, D. Kirn, S. Han, 2008, The Lancet. Oncology.

Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response.

D. Kirn, C. Brugnara, T. J. Schneider, 1994, The American journal of medicine.